Anatara Lifesciences (ASX: ANR) Provides GaRP-IBS Trial Update
Recruitment Milestones
Anatara Lifesciences (ASX: ANR) reports substantial progress in the recruitment for Stage 2 of its pivotal GaRP-IBS trial. Approximately 60 participants have been enrolled, with an additional 25 candidates in the final screening stage. The trial will pause recruitment on 13 December 2024 after meeting the anticipated minimum requirement.
CEO Comments
Dr. David Brookes, Executive Chair of Anatara Lifesciences, stated, “Progress has continued at a satisfactory rate, and we are pleased to move towards the minimum number of 60 participants sought for Stage 2. This only leaves a short window for new participants to get involved.” He encouraged eligible IBS sufferers to express interest in participating in the trial before the deadline.
Trial Design and Expectations
The trial will involve participants randomised into two groups receiving either the GaRP product or a placebo over an eight-week period, followed by a two-week follow-up. This phase aims to confirm the interim results from Stage 1, as the total patient count for analysis is expected to reach 100 to 140.
Market Opportunities
The GaRP product has the potential to become a significant treatment option for irritable bowel syndrome, addressing an unmet need due to a lack of effective gastrointestinal treatments. The commercial opportunity for non-prescription gastrointestinal products in the US market is estimated at US$8 billion.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.